Agentix's Mounting Losses Signal Financial Strain
Ticker: AGTX · Form: 10-K · Filed: Jul 16, 2025 · CIK: 1603345
| Field | Detail |
|---|---|
| Company | Agentix CORP. (AGTX) |
| Form Type | 10-K |
| Filed Date | Jul 16, 2025 |
| Risk Level | high |
| Sentiment | bearish |
Sentiment: bearish
Topics: Biotechnology, Net Loss, High-Interest Debt, Convertible Notes, Financial Risk, Liquidity Concerns, SEC Filing Analysis
TL;DR
**AGTX is bleeding cash and piling on high-interest debt; steer clear unless you're a high-risk speculator.**
AI Summary
Agentix Corp. (AGTX) reported a net loss of $433,497 for the fiscal year ended March 31, 2025, a significant increase from the prior year. The company's revenue streams include 'Services' and 'Software Subscription,' though specific dollar amounts for these categories were not detailed for the current fiscal year. A key business change involved a convertible promissory note issued on July 14, 2025, bearing an initial interest rate of 7.5% for 30 days, then escalating to 2% per month. This note, with a principal amount of $103,350, highlights a reliance on debt financing. Risks include the high interest rate on this note and the company's accumulated deficit, which stood at $433,497 as of March 31, 2025. The strategic outlook appears focused on managing existing debt and potentially leveraging its 'Prepaid Software' and 'Clinical Research' assets, though no specific forward-looking revenue projections were provided. The company also engaged with 'SBS Management' and 'Grays Peak' for various services, indicating ongoing operational expenditures.
Why It Matters
Agentix Corp.'s substantial net loss of $433,497 and reliance on high-interest debt, like the 2% monthly rate on its $103,350 note, signals significant financial instability for investors. This could lead to further dilution if more equity is issued or potential bankruptcy if debt obligations are not met, impacting employees' job security and customers' confidence in long-term service availability. In the competitive biological products sector, Agentix's financial struggles could make it an acquisition target or lead to its marginalization, affecting market dynamics and innovation. The company's ability to compete with more financially robust peers is severely hampered by its current capital structure.
Risk Assessment
Risk Level: high — Agentix Corp. faces high risk due to a net loss of $433,497 for FY2025 and a convertible promissory note issued July 14, 2025, with an escalating interest rate from 7.5% to 2% per month. This aggressive debt financing, coupled with an accumulated deficit of $433,497, indicates severe liquidity challenges and a high probability of further dilution or financial distress.
Analyst Insight
Investors should avoid Agentix Corp. (AGTX) given its significant net loss of $433,497 and reliance on high-interest debt. The escalating interest on the $103,350 convertible note presents an unsustainable financial burden, suggesting a high risk of capital loss.
Revenue Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Services | ||
| Software Subscription |
Key Numbers
- $433,497 — Net Loss (Reported for the fiscal year ended March 31, 2025, indicating significant unprofitability.)
- $103,350 — Convertible Promissory Note Principal (Issued on July 14, 2025, highlighting reliance on debt financing.)
- 7.5% — Initial Interest Rate (On the convertible note for the first 30 days, indicating high cost of capital.)
- 2% — Monthly Interest Rate (On the convertible note after 30 days, representing an annualized rate of 24%, which is extremely high.)
- 40,066,951 — Common Stock Shares Outstanding (As of March 31, 2025, indicating potential for dilution with convertible debt.)
Key Players & Entities
- Agentix Corp. (company) — filer of 10-K
- SBS Management (company) — service provider to Agentix Corp.
- Grays Peak (company) — service provider to Agentix Corp.
- GSL Healthcare (company) — entity mentioned in financial statements
- FairWind Energy Inc. (company) — former name of Agentix Corp.
- 03 Life Sciences (company) — organization name associated with filer
FAQ
What was Agentix Corp.'s net income for the fiscal year 2025?
Agentix Corp. reported a net loss of $433,497 for the fiscal year ended March 31, 2025, indicating significant unprofitability.
What is the interest rate on Agentix Corp.'s new convertible promissory note?
The convertible promissory note issued on July 14, 2025, bears an initial interest rate of 7.5% for 30 days, escalating to 2% per month thereafter.
What is the principal amount of the convertible note issued by Agentix Corp.?
The principal amount of the convertible promissory note issued by Agentix Corp. on July 14, 2025, is $103,350.
What are the primary risks highlighted in Agentix Corp.'s 10-K filing?
Primary risks include the substantial net loss of $433,497, the high and escalating interest rates on the $103,350 convertible note, and the accumulated deficit, all pointing to significant financial instability.
How many common stock shares were outstanding for Agentix Corp. as of March 31, 2025?
As of March 31, 2025, Agentix Corp. had 40,066,951 common stock shares outstanding.
What was Agentix Corp.'s previous company name?
Agentix Corp.'s former company name was FairWind Energy Inc., with the name change occurring on March 21, 2014.
Where is Agentix Corp.'s business address located?
Agentix Corp.'s business address is 32932 Pacific Coast Highway, #14-254, Dana Point, CA 92629.
What is the fiscal year end for Agentix Corp.?
Agentix Corp.'s fiscal year ends on March 31, as indicated by the 'CONFORMED PERIOD OF REPORT: 20250331' in the filing.
What is the significance of the 2% per month interest rate on Agentix Corp.'s convertible note?
The 2% per month interest rate, equivalent to an annualized 24%, is exceptionally high and indicates Agentix Corp.'s difficulty in securing more favorable financing, posing a severe burden on its cash flow.
What services or products does Agentix Corp. offer based on the filing?
Agentix Corp. generates revenue from 'Services' and 'Software Subscription' offerings, and also mentions 'Prepaid Software' and 'Clinical Research' in its assets, suggesting a focus on biological products and related services.
Risk Factors
- High Cost of Debt Financing [high — financial]: The company issued a convertible promissory note on July 14, 2025, with an initial interest rate of 7.5% for 30 days, escalating to 2% per month thereafter. This monthly rate equates to an annualized rate of 24%, which is exceptionally high and indicative of significant financial distress or a lack of access to more favorable financing options.
- Accumulated Deficit [high — financial]: As of March 31, 2025, Agentix Corp. has an accumulated deficit of $433,497. This indicates that the company has incurred more expenses than revenues over its lifetime, raising concerns about its long-term financial viability and ability to achieve profitability.
- Reliance on Debt [medium — financial]: The issuance of a $103,350 convertible promissory note highlights a reliance on debt financing. This can increase financial risk, especially given the high interest rates associated with the note, and may lead to future dilution if converted.
- Dependence on Service Providers [medium — operational]: The company engaged with 'SBS Management' and 'Grays Peak' for various services during the fiscal year. While specific costs are not detailed, these engagements represent ongoing operational expenditures that contribute to the company's overall cost structure.
- Potential for Share Dilution [medium — financial]: The company has 40,066,951 common stock shares outstanding as of March 31, 2025. The convertible promissory note, if converted, could lead to a significant increase in the number of outstanding shares, thereby diluting existing shareholders' ownership.
Industry Context
Agentix Corp. operates within the biological products sector, specifically excluding diagnostic substances. This industry is characterized by high research and development costs, long product development cycles, and significant regulatory hurdles. Companies in this space often rely on substantial funding to advance their pipelines, making access to capital and efficient financial management critical for survival and growth.
Regulatory Implications
As a company in the biological products sector, Agentix Corp. is subject to stringent regulations from bodies like the FDA. Compliance with Good Manufacturing Practices (GMP) and other regulatory standards is essential for product development and market access. Failure to comply can result in significant delays, fines, or product recalls, impacting financial performance and operational continuity.
What Investors Should Do
- Monitor debt covenants and repayment schedules.
- Evaluate the potential impact of debt conversion on share dilution.
- Seek clarity on revenue generation from 'Services' and 'Software Subscription'.
Key Dates
- 2025-03-31: Fiscal Year End — Marks the end of the reporting period for which the 10-K was filed, with a reported net loss of $433,497 and an accumulated deficit of the same amount.
- 2025-07-14: Convertible Promissory Note Issued — A $103,350 note was issued with a high interest rate (7.5% for 30 days, then 2% per month), indicating current financing challenges and a high cost of capital.
- 2025-07-16: 10-K Filing Date — The company officially filed its annual report, providing a comprehensive overview of its financial performance and condition for the fiscal year ended March 31, 2025.
Glossary
- Accumulated Deficit
- The cumulative net losses of a company that have not been offset by net income or other gains. It represents a negative retained earnings balance. (Agentix Corp. has an accumulated deficit of $433,497 as of March 31, 2025, indicating a history of unprofitability.)
- Convertible Promissory Note
- A debt instrument that can be converted into a predetermined amount of equity in the issuing company. It typically carries interest. (Agentix Corp. issued a $103,350 convertible note with a high interest rate, highlighting its financing strategy and potential for future dilution.)
- Fiscal Year End
- The end of a company's accounting period, which does not necessarily coincide with the calendar year. For Agentix Corp., it is March 31. (The financial results reported in the 10-K are for the period ending March 31, 2025.)
Year-Over-Year Comparison
The fiscal year ended March 31, 2025, shows a net loss of $433,497, a significant increase from the prior year's performance (specific prior year net income/loss not detailed here). Revenue streams like 'Services' and 'Software Subscription' were not quantified for the current year, making direct revenue growth comparison impossible. The most notable change is the issuance of a high-interest convertible promissory note, indicating increased financial risk and a shift towards debt financing compared to the previous reporting period.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on July 16, 2025 regarding Agentix Corp. (AGTX).